Remarks

By the present amendment, applicants have canceled claims 11-17 and added new claims 18-19. Support for new claim 18 is found in canceled Claim 11. Support for new claim 19 is found in claim 2 and in canceled claims 12-17. In addition, the claims have been amended to eliminate multiple dependencies and to place the claims in proper format. No new matter has been added. Therefore, the claims remaining for consideration by the Examiner are claims 1-10 and 18-19.

The foregoing amendments to the specification are to insert the priority provisional application information, for which this application claims benefit. The Abstract has been added as a separate sheet, and should be inserted following the claims in the specification.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (609) 627-8507

Date: August 28, 2006

John D. Thallemer Attorney for Applicants Reg. No. 34,940